These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

514 related articles for article (PubMed ID: 26254228)

  • 1. Clinical significance of dual-time-point 18F-FDG PET imaging in resectable non-small cell lung cancer.
    Shimizu K; Okita R; Saisho S; Yukawa T; Maeda A; Nojima Y; Nakata M
    Ann Nucl Med; 2015 Dec; 29(10):854-60. PubMed ID: 26254228
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Significance of dual-time-point 18F-FDG PET imaging in evaluation of hilar and mediastinal lymph node metastasis in non-small-cell lung cancer].
    Hu M; Yu JM; Liu NB; Liu LP; Guo HB; Yang GR; Zhang PL; Xu XQ
    Zhonghua Zhong Liu Za Zhi; 2008 Apr; 30(4):306-9. PubMed ID: 18788639
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dual-time-point FDG-PET for evaluation of lymph node metastasis in patients with non-small-cell lung cancer.
    Nishiyama Y; Yamamoto Y; Kimura N; Ishikawa S; Sasakawa Y; Ohkawa M
    Ann Nucl Med; 2008 May; 22(4):245-50. PubMed ID: 18535874
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The maximum standardized uptake value of fluorodeoxyglucose positron emission tomography of the primary tumour is a good predictor of pathological nodal involvement in clinical N0 non-small-cell lung cancer.
    Miyasaka Y; Suzuki K; Takamochi K; Matsunaga T; Oh S
    Eur J Cardiothorac Surg; 2013 Jul; 44(1):83-7. PubMed ID: 23233074
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictive value of primary fluorine-18 fluorodeoxyglucose standard uptake value for a better choice of systematic nodal dissection or sampling in clinical stage ia non--small-cell lung cancer.
    Li X; Zhang H; Xing L; Xu X; Xie P; Ma H; Zhang L; Chen M; Sun X; Xu W; Chen L; Yu J
    Clin Lung Cancer; 2013 Sep; 14(5):568-73. PubMed ID: 23835164
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic Significance of FDG Uptake of Bone Marrow on PET/CT in Patients With Non-Small-Cell Lung Cancer After Curative Surgical Resection.
    Lee JW; Na JO; Kang DY; Lee SY; Lee SM
    Clin Lung Cancer; 2017 Mar; 18(2):198-206. PubMed ID: 27495385
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 18F-FDG uptake as a biologic prognostic factor for recurrence in patients with surgically resected non-small cell lung cancer.
    Higashi K; Ueda Y; Arisaka Y; Sakuma T; Nambu Y; Oguchi M; Seki H; Taki S; Tonami H; Yamamoto I
    J Nucl Med; 2002 Jan; 43(1):39-45. PubMed ID: 11801701
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Integrated FDG-PET/CT does not make invasive staging of the intrathoracic lymph nodes in non-small cell lung cancer redundant: a prospective study.
    Tournoy KG; Maddens S; Gosselin R; Van Maele G; van Meerbeeck JP; Kelles A
    Thorax; 2007 Aug; 62(8):696-701. PubMed ID: 17687098
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Limited predictive value of dual-time-point F-18 FDG PET/CT for evaluation of pathologic N1 status in NSCLC patients.
    Kim SJ; Kim YK; Kim IJ; Kim YD; Lee MK
    Clin Nucl Med; 2011 Jun; 36(6):434-9. PubMed ID: 21552019
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic value of metabolic tumor burden from (18)F-FDG PET in surgical patients with non-small-cell lung cancer.
    Zhang H; Wroblewski K; Liao S; Kampalath R; Penney BC; Zhang Y; Pu Y
    Acad Radiol; 2013 Jan; 20(1):32-40. PubMed ID: 22999369
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk factors for mediastinal lymph node metastasis in non-small-cell lung cancer by PET/CT.
    Xu ZQ; Xie LJ; Fan W; Duan XB; Cheng MH
    Nucl Med Commun; 2014 May; 35(5):466-71. PubMed ID: 24535381
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 18F-FDG uptake by primary tumor as a predictor of intratumoral lymphatic vessel invasion and lymph node involvement in non-small cell lung cancer: analysis of a multicenter study.
    Higashi K; Ito K; Hiramatsu Y; Ishikawa T; Sakuma T; Matsunari I; Kuga G; Miura K; Higuchi T; Tonami H; Yamamoto I
    J Nucl Med; 2005 Feb; 46(2):267-73. PubMed ID: 15695786
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Limited prognostic value of dual time point F-18 FDG PET/CT in patients with early stage (stage I & II) non-small cell lung cancer (NSCLC).
    Kim SJ; Kim YK; Kim IJ; Kim YD; Lee MK
    Radiother Oncol; 2011 Jan; 98(1):105-8. PubMed ID: 21159395
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic value of SUVmax and metabolic tumor volume on 18F-FDG PET/CT in early stage non-small cell lung cancer patients without LN metastasis.
    Yoo IeR; Chung SK; Park HL; Choi WH; Kim YK; Lee KY; Wang YP
    Biomed Mater Eng; 2014; 24(6):3091-103. PubMed ID: 25227018
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Occult nodal metastasis in patients with non-small cell lung cancer at clinical stage IA by PET/CT.
    Park HK; Jeon K; Koh WJ; Suh GY; Kim H; Kwon OJ; Chung MP; Lee KS; Shim YM; Han J; Um SW
    Respirology; 2010 Nov; 15(8):1179-84. PubMed ID: 20573058
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Value of dual time point F-18 FDG-PET/CT imaging for the evaluation of prognosis and risk factors for recurrence in patients with stage I non-small cell lung cancer treated with stereotactic body radiation therapy.
    Satoh Y; Nambu A; Onishi H; Sawada E; Tominaga L; Kuriyama K; Komiyama T; Marino K; Aoki S; Araya M; Saito R; Maehata Y; Oguri M; Araki T
    Eur J Radiol; 2012 Nov; 81(11):3530-4. PubMed ID: 22178287
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk factors for predicting the occult nodal metastasis in T1-2N0M0 NSCLC patients staged by PET/CT: potential value in the clinic.
    Li L; Ren S; Zhang Y; Guan Y; Zhao J; Liu J; Wang Q; Chen G; Chen H; Xiang J; Fu X
    Lung Cancer; 2013 Aug; 81(2):213-7. PubMed ID: 23664030
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic value of dual-time-point 18F-FDG PET-CT imaging in patients with head and neck squamous cell carcinoma.
    Abgral R; Le Roux PY; Rousset J; Querellou S; Valette G; Nowak E; Turzo A; Tissot V; Marianowski R; Salaün PY
    Nucl Med Commun; 2013 Jun; 34(6):551-6. PubMed ID: 23587836
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Are discordant positron emission tomography and pathological assessments of the mediastinum in non-small cell lung cancer significant?
    Tandberg DJ; Gee NG; Chino JP; D'Amico TA; Ready NE; Coleman RE; Kelsey CR
    J Thorac Cardiovasc Surg; 2013 Oct; 146(4):796-801. PubMed ID: 23870158
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An Investigation of the Relationship Between
    Kandemir O; Demir F
    Curr Radiopharm; 2024; 17(1):111-116. PubMed ID: 37644744
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.